MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research Jun 3, 2021
MindCure’s Kelsey Ramsden on Psychedelic Rollout: It’s Not Just Regulation; It’s Research Apr 26, 2021
Psychedelics are Now Decriminalized in D.C., Advocates Push for Further Legislative Changes Mar 15, 2021
Pandemic Provides Opportunity for Evaluation of Mental Health; MindCure and MindMed Lead With Ibogaine Mar 8, 2021
